Investor Relations

Company Profile

REVA Medical, Inc. (“REVA” or the “Company”) is a medical device company located in San Diego, California, USA, that has developed and commercialized a proprietary bioresorbable scaffold, as an alternative to metal stents, to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents.

The Company’s Fantom® scaffold, which received European CE Marking on April 3, 2017, is designed to offer an ideal balance of thinness and strength, with distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. Commercialization of Fantom is currently underway in select centers in Europe.

REVA is a Delaware corporation with its corporate headquarters located in San Diego, California. REVA securities are traded on the Australian Securities Exchange ("ASX") under the symbol RVA. REVA’s international ticker symbol is RVA.AX. Its securities trade in the form of CHESS Depositary Interests ("CDIs"). The Company is also registered with the United States Securities and Exchange Commission (“SEC”), however its securities are currently not traded on any U.S. exchange.

Key Investor Facts

Trading Exchange

Australian Securities Exchange (“ASX”)

Australian Ticker Symbol

RVA

International Ticker Symbol

RVA.AX

Ratio of CDIs to shares of common stock

1:10

Number of CDIs outstanding*

428,514,770

Number of shares of common stock outstanding*

42,851,477

Australian Registered Body Number (ARBN)

146 505 777

* As of May 1, 2017